We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App





Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022

CellaVision (Lund, Sweden) has announced the launch of DIFF-Line by CellaVision, a new workflow solution for low-volume hematology laboratories at the 2022 AACC Clinical Lab Expo. More...

DIFF-Line by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision DC-1, RAL SmearBox, and RAL StainBox.

CellaVision DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision DC-1 was launched in 2019 and received FDA clearance in October 2020.

RAL SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market today July 27, 2022.

RAL StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.

DIFF-Line by CellaVision is available on the European market from July 2022 and will be rolled out in more markets in 2022. All CellaVision products are sold through their distribution partners.

“DIFF-Line by CellaVision is a comprehensive solution for small labs that want to improve diagnostic certainty,” said Simon Ostergaard, CellaVision CEO. “With the acquisition of RAL Diagnostics, CellaVision can now offer a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples.”

Related Links:
CellaVision 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.